MYD88 and B-cell non-Hodgkin lymphoma: The discovery of the activating mutation of MYD88 (MYD88L265P being the far most frequent) in more than 90% of WM cases contributed to the concept that this entity is genetically distinct from other B-cell lymphomas (3, 4).